reports
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Lidocaine to be approved in 2017
​Maintain HOLD; no near-term progress on ANDA approval: TWi Pharma’s 1-5M16 sales grew by 164% YoY to NT$300 mn, in line with our estimate. However, the company remains unprofitable despite the sales contribution from four products launched in 2015, with a 1Q16 LPS of NT$1.75. We expect 2016F LPS to reach NT$2.37. The key to turning profitable is Lidocaine and Dexlansoprazole, the launch schedules of which remain unclear for now. Actavis’s generic Lidocaine has been on the market for more ...
TWi Pharma: Product launch delays; sales miss - 4180 TT; HOLD-OPF
​We expect Zolpidem to be launched in 2H16, with limited earnings contribution due to a small market size. Lidocaine and Dexlansoprazole will remain the key earnings drivers, and focus areas, going forward, in our view. Given the delayed launch of the three generic drugs, growing business uncertainties and intensifying competition, we cut our forecasts and lower our TP.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.